Submit Manuscript  

Article Details


Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis

[ Vol. 16 , Issue. 13 ]

Author(s):

Tedman Ehlers, Scott Furness, Thomas Philip Robinson, Haizhen A. Zhong, David Goldsmith, Jack Aribser and J. Phillip Bowen   Pages 1478 - 1488 ( 11 )

Abstract:


Angiogenesis has been identified as a crucial process in the development and spread of cancers. There are many regulators of angiogenesis which are not yet fully understood. Methionine aminiopeptidase is a metalloenzyme with two structurally distinct forms in humans, Type-1 (MetAP-1) and Type-2 (MetAP-2). It has been shown that small molecule inhibitors of MetAP-2 suppress endothelial cell proliferation. The initial discovery by Donald Ingber of MetAP-2 inhibition as a potential target in angiogenesis began with a fortuitous observation similar to the discovery of penicillin activity by Sir Alexander Fleming. From a drug design perspective, MetAP-2 is an attractive target. Fumagillin and ovalicin, known natural products, bind with IC50 values in low nanomolar concentrations. Crystal structures of the bound complexes provide 3-dimensional coordinates for advanced computational studies. More recent discoveries have shown other biological activities for MetAP-2 inhibition, which has generated new interests in the design of novel inhibitors. Semisynthetic fumagillin derivatives such as AGM-1470 (TNP-470) have been shown to have better drug properties, but have not been very successful in clinical trials. The rationale and development of novel multicyclic analogs of fumagillin are reviewed.

Keywords:

ADME, Angiogenesis, Angiogenic inhibitors, Anti-angiogenic compounds, Cancer, Drug design, Fumagillin, Methionine aminiopeptidase, MetAP-2, Ovalicin, Pharmacophore, Cancer, TNP-470.

Affiliation:

Center for Drug Design, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, Georgia 30341, U.S.A

Graphical Abstract:



Read Full-Text article